Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 38, Issue 4, 2005, Pages 720-733

  Mullen, John H ^a   Shugert, Richard L ^a   Ponsler, George D ^a   Li, Qimin ^a   Sundaram, Bhaskar ^b   Coales, Heather L ^b   Yakupkovic, Joseph E ^b,c   LeLacheur, Richard M ^b   Wheeler, William J ^a   Belas, Frank J ^a   Sauer, John Michael ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b Taylor Technology Inc   (United States)

^c A Division of Microbac   (United States)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

ADHD; Bioanalytical; Chromatography; Clinical; Mass spectrometry; Quantification; Straterra

Indexed keywords

4 HYDROXYATOMOXETINE; 4 HYDROXYATOMOXETINE O GLUCURONIDE; ATOMOXETINE; DRUG METABOLITE; GLUCURONIDE; N NORATOMOXETINE; STRATERRA; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL ERROR; ARTICLE; BLOOD ANALYSIS; DRUG DETERMINATION; DRUG STABILITY; HIGH THROUGHPUT SCREENING; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; REFERENCE VALUE; TANDEM MASS SPECTROMETRY; URINALYSIS;

BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, LIQUID; GLUCURONIDES; HUMANS; MASS SPECTROMETRY; OXIDATION-REDUCTION; PROPYLAMINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 20644472444     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.02.007     Document Type: Article

References (16)

1. D.T. Wong, P.G. Threlkeld, K.L. Best, and F.P. Bymaster J. Pharmacol. Exp. Ther. 222 1982 61 65
2. D.R. Gehlert, S.L. Gackenheimer, and D.W. Robertson Neurosci. Lett. 157 1993 203 206
3. T. Spencer, J. Biederman, T. Wilens, M. Harding, D. ODonnell, and S. Griffin Child Adolesc. Psych. 35 1996 409 432
4. J.M. Swanson, J.A. Sergeant, E.J.S. Sonuga-Barke, P.S. Jensen, and D.P. Cantwell Lancet 351 1998 429 433
5. G. Weiss Psychopharmacol. Bull. 21 1985 169 177
6. R. Pary, S. Lewis, P.R. Matuschka, P. Rudzinskiy, M. Safi, and S. Lippmann Ann. Clin. Psychiatry 14 2002 105 111
7. L.A. Adler, and H.C. Chua J. Clin. Psychol. 63 2002 29 35
8. C. Samson PSTT 2 1999 307 308
9. R. Kuczenski, and DS. Segal J. Neurochem. 68 1997 2032 2037
10. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Neuropsychopharmacology 27 2002 699 711
11. J.W. Tidey, and J. Bergman J. Pharmacol. Exp. Ther. 285 1998 1163 1174
12. J.M. Sauer, G.D. Ponsler, E.L. Mattiuz, A.J. Long, J.W. Witcher, H.R. Thomasson, and K.A. Desante Drug Metab. Dispos. 31 2003 98 107
13. B.J. Ring, J.S. Gillespie, J.A. Eckstein, and S.A. Wrighton Drug Metab. Dispos. 30 2002 319 323
14. N.A. Farid, R.F. Bergstrom, E.A. Ziege, C.J. Parli, and L. Lemberger J. Clin. Pharmacol. 25 1985 296 301
15. D.A.P. Evans, A. Maghoub, T.P. Sloan, J.R. Idle, and R.L. Smith J. Med. Genet. 17 1980 102 105
16. E. Steiner, L. Bertilsson, J. Sawe, I. Bertling, and F. Sjoqvist Clin. Pharmacol. Ther. 44 1988 431 435